Anixa Biosciences, Inc. (NASDAQ:ANIX) Sees Large Decrease in Short Interest

Anixa Biosciences, Inc. (NASDAQ:ANIX - Get Free Report) was the recipient of a large decline in short interest in October. As of October 31st, there was short interest totalling 421,900 shares, a decline of 28.9% from the October 15th total of 593,700 shares. Based on an average trading volume of 75,800 shares, the short-interest ratio is presently 5.6 days. Currently, 1.4% of the company's stock are sold short.

Anixa Biosciences Price Performance

NASDAQ ANIX traded up $0.03 on Thursday, reaching $3.13. The stock had a trading volume of 81,012 shares, compared to its average volume of 109,602. The firm has a fifty day moving average of $3.27 and a two-hundred day moving average of $2.99. Anixa Biosciences has a 1-year low of $2.14 and a 1-year high of $5.13. The company has a market cap of $100.72 million, a P/E ratio of -8.03 and a beta of 0.84.

Anixa Biosciences (NASDAQ:ANIX - Get Free Report) last released its earnings results on Friday, September 6th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.01. Research analysts predict that Anixa Biosciences will post -0.42 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on ANIX shares. HC Wainwright reiterated a "buy" rating and set a $7.00 price objective on shares of Anixa Biosciences in a research note on Tuesday, September 17th. EF Hutton Acquisition Co. I upgraded Anixa Biosciences to a "strong-buy" rating in a research note on Wednesday, August 7th.

Institutional Trading of Anixa Biosciences

Several institutional investors and hedge funds have recently modified their holdings of the business. Virtu Financial LLC raised its position in Anixa Biosciences by 47.2% in the first quarter. Virtu Financial LLC now owns 16,156 shares of the company's stock valued at $50,000 after purchasing an additional 5,183 shares during the last quarter. Nations Financial Group Inc. IA ADV grew its stake in Anixa Biosciences by 50.0% during the second quarter. Nations Financial Group Inc. IA ADV now owns 22,500 shares of the company's stock worth $50,000 after purchasing an additional 7,500 shares during the period. Concorde Asset Management LLC acquired a new stake in Anixa Biosciences during the second quarter worth approximately $31,000. Tyler Stone Wealth Management grew its stake in Anixa Biosciences by 100.0% during the third quarter. Tyler Stone Wealth Management now owns 42,016 shares of the company's stock worth $132,000 after purchasing an additional 21,008 shares during the period. Finally, International Assets Investment Management LLC grew its stake in Anixa Biosciences by 170.0% in the third quarter. International Assets Investment Management LLC now owns 37,800 shares of the company's stock valued at $1,190,000 after acquiring an additional 23,800 shares during the period. 29.13% of the stock is currently owned by institutional investors.

About Anixa Biosciences

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.